CDT logo

CDT Equity Inc. Stock Price

NasdaqCM:CDT Community·US$933.9k Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

CDT Share Price Performance

US$2.46
-1285.14 (-99.81%)
US$2.46
-1285.14 (-99.81%)
Price US$2.46

CDT Community Narratives

There are no narratives available yet.

Snowflake Analysis

Medium-low risk with mediocre balance sheet.

6 Risks
0 Rewards

CDT Equity Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$19.6m

Other Expenses

-US$19.6m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
-51.33
0%
0%
53.3%
View Full Analysis

About CDT

Founded
2019
Employees
6
CEO
Andrew Regan
WebsiteView website
www.conduitpharma.com

CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Recent CDT News & Updates

Recent updates

No updates